☆ 4.7 Article

1,3-Dicaffeoylquinic acid targeting 14-3-3 tau suppresses human breast cancer cell proliferation and metastasis through IL6/JAK2/PI3K pathway

BIOCHEMICAL PHARMACOLOGY (2020)

Journal

BIOCHEMICAL PHARMACOLOGY

Volume 172, Issue -, Pages -

Publisher

PERGAMON-ELSEVIER SCIENCE LTD

DOI: 10.1016/j.bcp.2019.113752

Keywords

13-DCQA; 14-3-3 tau; Breast cancer; Metastasis; Apoptosis

Funding

Tackle Key Problems in Science and Technology Project in Anhui Province, China [1501041177]
Promoting Project for Team Construction of Anhui Province, China [Z010115006]
Natural Science Foundation Project of Anhui Province [1908085MC87]
Scientific Research Foundation of Anhui University [10117700023]
Academic & Technology Leaders Introduction Project of Anhui University [10117700023]
211 Project of Anhui University [10117700023]

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Abstract

14-3-3 tau plays a critical role in tumorigenesis and metastasis of breast cancer and can be used as new drug target protein. Dicaffeoylquinic acids (DCQAs), natural products, have antioxidant, antimicrobial, and anti-inflammatory activities. In this study, the anticancer effects of DCQAs on breast cancer cells MCF-7, MDA-MB-231 cell lines and mechanism in triple negative breast cancer (TNBC) were investigated. First, we screened for DCQAs that could bind to 14-3-3 tau and had a significant inhibitory effect on breast cancer cells. MTT, colony formation, transwell migration, and flow cytometric assays revealed that 1,3-DCQA was the best one of 14-3-3 tau binding protein from DCQAs against breast cancer cell proliferation and metastasis but safe for normal cells. Through molecular docking simulation, overexpression and knockdown assays, we confirmed that 14-3-3 tau was one of 1,3-DCQA target protein. Eukaryotic transcriptome sequencing and western blot analysis demonstrated that 1,3-DCQA binds to 14-3-3 tau to prevent breast cancer proliferation and metastasis via Jak/PI3K/Akt and Raf/ERK pathway, which promote IL6 and CSF3 expression raised by CREB (CREBBP, CREB5) and induced cell apoptosis via Bad/Bax/caspase 9 signaling pathway. Our results provided evidence that 1,3-DCQA can be used as a novel lead compound against breast cancer by inhibition of 14-3-3 protein.

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

14-3-3τ drives estrogen receptor loss via ERa36 induction and GATA3 inhibition in breast cancer

Lidija A. Wilhelms Garan, Yang Xiao, Weei-Chin Lin

Summary: This study reveals that approximately one-fourth of recurrent ER+ breast cancers lose ER expression, leading to endocrine therapy failure. 14-3-3 tau, which is up-regulated in about 60% of breast cancer, drives the conversion of ER+ to ER- and EMT. ER alpha 36 is identified as a downstream effector of 14-3-3 tau and can antagonize ER alpha 66. Additionally, GATA3 represses the promoter of ER alpha 36 and its phosphorylation by AKT plays a role in this regulation. Furthermore, the collaboration between 14-3-3 tau and AKT is demonstrated in ER alpha 36 induction and endocrine therapy resistance.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)